ATE237324T1 - Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen - Google Patents

Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen

Info

Publication number: ATE237324T1
Authority: AT; Austria
Prior art keywords: pharmaceutical compositions; compositions; neuroprotective pharmaceutical; effective; dexanabinol derivatives
Prior art date: 1994-02-07

Application number

AT95909482T

Other languages

English (en)

Inventor

Raphael Mechoulam

Emil Pop

Mordechai Sokolovsky

Yoel Kloog

Anat Biegon

Original Assignee

Univ Ramot

Yissum Res Dev Co

Pharmos Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-02-07

Filing date

1995-02-06

Publication date

2003-05-15

1995-02-06 Application filed by Univ Ramot, Yissum Res Dev Co, Pharmos Corp filed Critical Univ Ramot

2003-05-15 Application granted granted Critical

2003-05-15 Publication of ATE237324T1 publication Critical patent/ATE237324T1/de

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract 2
SSQJFGMEZBFMNV-PMACEKPBSA-N dexanabinol Chemical class C1C(CO)=CC[C@@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@H]21 SSQJFGMEZBFMNV-PMACEKPBSA-N 0.000 title 1
230000000324 neuroprotective effect Effects 0.000 title 1
206010029350 Neurotoxicity Diseases 0.000 abstract 2
206010044221 Toxic encephalopathy Diseases 0.000 abstract 2
230000007135 neurotoxicity Effects 0.000 abstract 2
231100000228 neurotoxicity Toxicity 0.000 abstract 2
208000010496 Heart Arrest Diseases 0.000 abstract 1
208000005374 Poisoning Diseases 0.000 abstract 1
208000006011 Stroke Diseases 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
230000009692 acute damage Effects 0.000 abstract 1
230000036770 blood supply Effects 0.000 abstract 1
210000003169 central nervous system Anatomy 0.000 abstract 1
230000001684 chronic effect Effects 0.000 abstract 1
230000001010 compromised effect Effects 0.000 abstract 1
HCAWPGARWVBULJ-IAGOWNOFSA-N delta8-THC Chemical class C1C(C)=CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 HCAWPGARWVBULJ-IAGOWNOFSA-N 0.000 abstract 1
208000014674 injury Diseases 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000004770 neurodegeneration Effects 0.000 abstract 1
208000015122 neurodegenerative disease Diseases 0.000 abstract 1
231100000572 poisoning Toxicity 0.000 abstract 1
230000000607 poisoning effect Effects 0.000 abstract 1
230000002829 reductive effect Effects 0.000 abstract 1
230000000707 stereoselective effect Effects 0.000 abstract 1
230000008733 trauma Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Pyrane Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

AT95909482T 1994-02-07 1995-02-06 Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen ATE237324T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/192,886 US5521215A (en)	1989-11-07	1994-02-07	NMDA-blocking pharmaceuticals
PCT/US1995/001470 WO1995020958A1 (en)	1994-02-07	1995-02-06	Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions

Publications (1)

Publication Number	Publication Date
ATE237324T1 true ATE237324T1 (de)	2003-05-15

Family

ID=22711431

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95909482T ATE237324T1 (de)	1994-02-07	1995-02-06	Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen

Country Status (10)

Country	Link
US (1)	US5521215A (de)
EP (1)	EP0765160B1 (de)
JP (1)	JPH09511493A (de)
AT (1)	ATE237324T1 (de)
AU (1)	AU690221B2 (de)
CA (1)	CA2183466A1 (de)
DE (1)	DE69530389T2 (de)
IL (1)	IL112572A0 (de)
SG (1)	SG49625A1 (de)
WO (1)	WO1995020958A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5455279A (en) *	1991-04-19	1995-10-03	The Children's Medical Center Corporation	Regimen method of mediating neuronal damage using nitroglycerine
US6299895B1 (en)	1997-03-24	2001-10-09	Neurotech S.A.	Device and method for treating ophthalmic diseases
US5904144A (en) *	1996-03-22	1999-05-18	Cytotherapeutics, Inc.	Method for treating ophthalmic diseases
US5824662A (en) *	1996-09-27	1998-10-20	Guilford Pharmaceuticals Inc.	Treatment of global and focal ischemia using naaladase inhibitors
US6017903A (en)	1996-09-27	2000-01-25	Guilford Pharmaceuticals Inc.	Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
CA2264043A1 (en)	1996-09-27	1998-04-02	Guilford Pharmaceuticals Inc.	Naaladase compositions and methods for treating glutamate abnormality and effecting neuronal activity in animals
DE19706903A1 (de) *	1997-02-21	1998-08-27	Bayer Ag	Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1
JP2002501510A (ja) *	1997-05-07	2002-01-15	ユニメッド・ファーマシューティカルズ・インコーポレーテッド	ヒトにおける攪乱行動を改善し気分を高揚させる方法
AU727080B2 (en) *	1997-06-30	2000-11-30	Allergan, Inc.	Calcium blockers to treat proliferative vitreoretinopathy
US20050009884A1 (en) *	1997-06-30	2005-01-13	Dreyer Evan B.	Calcium blockers to treat proliferative retinal diseases
US6110139A (en) *	1997-10-21	2000-08-29	Loubser; Paul Gerhard	Retrograde perfusion monitoring and control system
AU9797598A (en) *	1997-11-14	1999-06-07	Alcon Laboratories, Inc.	Treatment of diabetic retinopathy
GB9807639D0 (en)	1998-04-14	1998-06-10	Kennedy Rheumatology Inst	Anti-inflammatory agents
US6630507B1 (en)	1998-04-21	2003-10-07	The United States Of America As Represented By The Department Of Health And Human Services	Cannabinoids as antioxidants and neuroprotectants
CA2340445A1 (en) *	1998-05-04	1999-11-11	The University Of Connecticut	Novel analgesic and immunomodulatory cannabinoids
US7897598B2 (en) *	1998-06-09	2011-03-01	Alexandros Makriyannis	Inhibitors of the anandamide transporter
US7589220B2 (en) *	1998-06-09	2009-09-15	University Of Connecticut	Inhibitors of the anandamide transporter
US7276613B1 (en)	1998-11-24	2007-10-02	University Of Connecticut	Retro-anandamides, high affinity and stability cannabinoid receptor ligands
US7161016B1 (en)	1998-11-24	2007-01-09	University Of Connecticut	Cannabimimetic lipid amides as useful medications
US7741365B2 (en) *	1999-10-18	2010-06-22	University Of Connecticut	Peripheral cannabinoid receptor (CB2) selective ligands
US7393842B2 (en) *	2001-08-31	2008-07-01	University Of Connecticut	Pyrazole analogs acting on cannabinoid receptors
US6900236B1 (en)	1999-10-18	2005-05-31	University Of Connecticut	Cannabimimetic indole derivatives
US6943266B1 (en) *	1999-10-18	2005-09-13	University Of Connecticut	Bicyclic cannabinoid agonists for the cannabinoid receptor
US8084467B2 (en) *	1999-10-18	2011-12-27	University Of Connecticut	Pyrazole derivatives as cannabinoid receptor antagonists
US7119108B1 (en)	1999-10-18	2006-10-10	University Of Connecticut	Pyrazole derivatives as cannabinoid receptor antagonists
CA2387764A1 (en)	1999-10-18	2001-04-26	University Of Connecticut	Peripheral cannabinoid receptor (cb2) selective ligands
EP1785417A3 (de) *	2000-06-22	2007-08-01	Pharmos Corporation	Neuartige nicht-psychotrope Cannabinoide
DE60125541T2 (de) *	2000-06-22	2007-10-11	Pharmos Corp.	Neue nicht psychotropische cannabinoide
US7235584B2 (en) *	2000-06-22	2007-06-26	Pharmos Corporation	Non-psychotropic cannabinoids
US8449908B2 (en) *	2000-12-22	2013-05-28	Alltranz, Llc	Transdermal delivery of cannabidiol
EP1361876A4 (de) *	2001-01-26	2004-03-31	Univ Connecticut	Neue cannabimimetische liganden
DE60237431D1 (de)	2001-01-29	2010-10-07	Univ Connecticut	Rezeptor-selektive cannabimimetische aminoalkylindole
DE60234246D1 (de) *	2001-04-06	2009-12-17	Univ Illinois	Cannabinoiden zur behandlung von während des schlafens auftretenden atmungsstörungen
JP4312594B2 (ja) *	2001-07-13	2009-08-12	ユニバーシティオブコネチカット	新規な二環式及び三環式カンナビノイド
US7666867B2 (en) *	2001-10-26	2010-02-23	University Of Connecticut	Heteroindanes: a new class of potent cannabimimetic ligands
US7029918B2 (en) *	2002-01-25	2006-04-18	Roche Diagnostics Operations, Inc.	Water-soluble derivatives of lipophilic drugs
AU2003265663A1 (en)	2002-08-23	2004-03-11	University Of Connecticut	Keto cannabinoids with therapeutic indications
WO2004021974A2 (en) *	2002-09-05	2004-03-18	Pharmos Corporation	Non-psychotropic cannabinoids for prevention of cognitive impairment
US20050192341A1 (en) *	2002-09-05	2005-09-01	Seth Kindler	Non-psychotropic cannabinoids for prevention of cognitive impairment
CA2507815A1 (en) *	2002-12-04	2004-06-17	Pharmos Corporation	High enantiomeric purity dexanabinol for pharmaceutical compositions
US8338648B2 (en) *	2004-06-12	2012-12-25	Signum Biosciences, Inc.	Topical compositions and methods for epithelial-related conditions
CA2623723A1 (en) *	2005-09-29	2007-04-12	Amr Technology, Inc.	Process for production of delta-9-tetrahydrocannabinol
DK2176208T3 (en) *	2007-07-30	2015-04-27	Zynerba Pharmaceuticals Inc	Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof
US20090247619A1 (en) *	2008-03-06	2009-10-01	University Of Kentucky	Cannabinoid-Containing Compositions and Methods for Their Use
WO2016036724A1 (en) *	2014-09-02	2016-03-10	The Texas A&M University System	Method of treating organophosphate intoxication
US9585867B2 (en)	2015-08-06	2017-03-07	Charles Everett Ankner	Cannabinod formulation for the sedation of a human or animal
CN110996926A (zh)	2017-07-20	2020-04-10	耶路撒冷希伯来大学伊萨姆研究开发有限公司	用于将亲脂性化合物递送进入和/或穿过皮肤的药物膜组合物
WO2019049145A1 (en)	2017-09-11	2019-03-14	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	COMPOSITIONS AND METHODS FOR NASAL BRAIN MEDICATION ADMINISTRATION FOR SYSTEMIC EFFECT
CA3116187A1 (en)	2017-11-29	2019-06-06	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Cannabinoids compositions and methods
US20220008354A1 (en)	2018-11-04	2022-01-13	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Orally administrable cannabinoids-containing compositions and methods
US12029718B2 (en)	2021-11-09	2024-07-09	Cct Sciences, Llc	Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1464695A (en) *	1974-06-24	1977-02-16	Smithkline Corp	Dibenzo-b,c-pyrans and pharmaceutical compositions thereof
IL48824A (en) *	1976-01-12	1980-05-30	Yissum Res Dev Co	Pharmaceutical compositions containing (3s,js) tetrahydrocanabinol derivatives and some novel compounds of this type
US4209520A (en) *	1977-06-17	1980-06-24	Pfizer Inc.	Hexahydro-1-hydroxy-9-hydroxymethyl-3-substituted-6H-dibenzo[b,d]pyrans as analgesic agents
US4133819A (en) *	1977-06-17	1979-01-09	Pfizer Inc.	Hexahydro-1-hydroxy-9-hydroxymethyl-3-substituted-6H-dibenzo[b,d]pyrans as analgesic agents
IL80411A (en) *	1986-10-24	1991-08-16	Raphael Mechoulam	Preparation of dibenzopyranol derivatives and pharmaceutical compositions containing them

1994
- 1994-02-07 US US08/192,886 patent/US5521215A/en not_active Expired - Lifetime
1995
- 1995-02-06 EP EP95909482A patent/EP0765160B1/de not_active Expired - Lifetime
- 1995-02-06 WO PCT/US1995/001470 patent/WO1995020958A1/en not_active Ceased
- 1995-02-06 AU AU17433/95A patent/AU690221B2/en not_active Ceased
- 1995-02-06 DE DE69530389T patent/DE69530389T2/de not_active Expired - Fee Related
- 1995-02-06 SG SG1996001470A patent/SG49625A1/en unknown
- 1995-02-06 CA CA002183466A patent/CA2183466A1/en not_active Abandoned
- 1995-02-06 AT AT95909482T patent/ATE237324T1/de not_active IP Right Cessation
- 1995-02-06 JP JP7520787A patent/JPH09511493A/ja active Pending
- 1995-02-07 IL IL11257295A patent/IL112572A0/xx active IP Right Grant

Also Published As

Publication number	Publication date
AU690221B2 (en)	1998-04-23
JPH09511493A (ja)	1997-11-18
SG49625A1 (en)	1998-06-15
WO1995020958A1 (en)	1995-08-10
EP0765160A1 (de)	1997-04-02
EP0765160A4 (de)	1997-04-09
DE69530389D1 (de)	2003-05-22
DE69530389T2 (de)	2004-03-25
US5521215A (en)	1996-05-28
AU1743395A (en)	1995-08-21
IL112572A0 (en)	1995-05-26
CA2183466A1 (en)	1995-08-10
EP0765160B1 (de)	2003-04-16

Legal Events

Date	Code	Title	Description
2003-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE237324T1 (de)	2003-05-15	Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen
EP1299374A4 (de)	2004-09-22	Neue nicht psychotropische cannabinoide
BG101118A (en)	1998-04-30	Therapeutical compounds
DE69636308D1 (de)	2006-08-10	Tumornekrosefaktor alpha (tnf-alpha) hemmende arzneistoffe
ATE203019T1 (de)	2001-07-15	Neue (r)-5-carbamoyl-8-fluor-3-n,n- disubstituierte-amino-3,4-dihydro-2h-1- benzopyrane
EE9800080A (et)	1998-10-15	(Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid
SE9604786D0 (sv)	1996-12-20	New compounds
BR9909358A (pt)	2000-12-12	Composto, composição farmacêutica, e, processo para prevenção ou alìvio de complicações crÈnicas decorrentes de diabetes melito
DE69531098D1 (de)	2003-07-24	Piperidine und pyrrolidine
CA2243404A1 (fr)	1998-05-28	Composes biaromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
CA2215470A1 (fr)	1997-08-14	Composes biaryles heterocycliques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
MX9501849A (es)	1997-02-28	Nuevos compuestos biciclicos-aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y sus usos.
AU2030497A (en)	1997-10-01	Propynyl or dienyl biaromatic compounds
EP1736470A3 (de)	2007-04-04	Pyrimidin-Derivate als cb2 Cannabinoid-Rezeptor Modulatoren
MX9403088A (es)	1997-02-28	Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
BR9809234A (pt)	2000-06-27	Composto, composição farmacêutica, uso de um composto, processos para tratar ou prevenir doenças do sistema endocrinológico, para fabricar um medicamento, para preparar um composto e um conjunto, conjunto, e, uso do mesmo.
CA2340734A1 (en)	2000-06-22	Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
ATE151774T1 (de)	1997-05-15	Cyclopentanperhydrophenanthren-17-beta-(3-furyl - 3-derivate und pharmazeutische präparate davon, zur behandlung von kardiovaskulär-erkrankungen
MXPA02003731A (es)	2003-12-11	Derivados novedosos de acido fusidico.
AU7076494A (en)	1995-01-17	Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of parkinson disease
EP1785417A3 (de)	2007-08-01	Neuartige nicht-psychotrope Cannabinoide
PT986390E (pt)	2003-01-31	Composicoes farmaceuticas que contem cicloridrato de cinchonina
BR9813098A (pt)	2000-08-15	Uso de glicosaminoglicans, preparação farmacêutica, e, combinaçào
MX9709684A (es)	1998-06-28	Uso de derivados de vitamina d4 para tratamiento de trastornos de la piel.
UA31266A (uk)	2000-12-15	Лікувальний засіб "дінальгін"